| Asthma
Arnuity Ellipta vs Rayos
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Arnuity Ellipta vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Arnuity Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Arnuity Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Arnuity Ellipta
Rayos
At A Glance
Oral inhalation
Once daily
Inhaled corticosteroid
Oral
Daily
Corticosteroid
Indications
- Asthma
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Asthma (>=12 years) 1 actuation of ARNUITY ELLIPTA 100 mcg or 200 mcg once daily by oral inhalation; starting dosage based on prior asthma therapy and disease severity; maximum 200 mcg once daily.
Asthma (5-11 years) 1 actuation of ARNUITY ELLIPTA 50 mcg once daily by oral inhalation.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate or any excipient
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=3%) Nasopharyngitis, headache, bronchitis, upper respiratory tract infection, pharyngitis, sinusitis, oral candidiasis, oropharyngeal candidiasis, oropharyngeal pain, toothache, gastroenteritis viral
Serious Hypertension, abscess, breast cancer, traumatic limb amputation, subarachnoid hemorrhage, intervertebral disc protrusion
Postmarketing Anaphylaxis, angioedema, rash, urticaria
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity that binds the human glucocorticoid receptor with high affinity (approximately 29.9 times that of dexamethasone), inhibiting pro-inflammatory transcription factors such as NFkB and mediators involved in asthma pathogenesis.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Arnuity Ellipta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (11/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Arnuity Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Arnuity Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Arnuity Ellipta.
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Arnuity ElliptaView full Arnuity Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.